GP681 not checked
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
FollowEvery change as it happens, and a Monday email
Trials
2 active
10 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Influenza, Human, Influenza
- Main trialPhase 3
- “This study will evaluate the efficacy, safety, and population pharmacokinetics of a single, oral dose of GP681 compared with placebo in patients aged 12 and older With Influenza at High Risk of Influenza Complications.”In the company’s words, NCT06573008 on ClinicalTrials.gov
- Other names
- Reference treatment · Test Treatment
Other drugs for Influenza, Human
- MRNA-1018-H5Moderna · Phase 3
- Baloxavir MarboxilRoche · Phase 3
- BRC-201Boryung Biopharma Co., Ltd. · Phase 3
- Dipyrone monohydrateBrainfarma Industria Química e Farmacêutica S/A · Phase 3
- CD388Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Phase 3
- MRNA Seasonal Flu vaccineGSK · Phase 3
Coming up1
- 30 Jul 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Dec 2025 | Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications | |
| Phase 3Recruiting | 30 Jul 2027 | Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza | |
| Phase 3Completed | 25 Apr 2023 | To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection | |
| Phase 2Completed | 18 Dec 2021 | A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza | |
| Phase 1Completed | 15 Dec 2020 | Evaluation the Safety and Tolerance of GP681 Tablets in Healthy Subjects | |
| Phase 1Completed | 22 Nov 2021 | A Phase I Mass Balance Study of [14C]GP681 in Healthy Chinese Male Volunteers | |
| Phase 1Completed | 3 Aug 2023 | GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers | |
| Phase 1Completed | 11 Sep 2023 | A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers | |
| Phase 1Completed | 18 Jan 2025 | Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension | |
| Phase 1Completed | 16 Feb 2025 | Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026